We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Conference Coverage · November 08, 2017

Predictive Genomic Markers of Response to VEGF Targeted Therapy (TT) in Metastatic Renal Cell Carcinoma (mRCC): Role of VHL and TP53 Mutation, and FLT1 Germline Variant

Written by
Andrew W. Hahn MD


Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading